Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 466,719 |
|
|||||
| News | - | ||||||
| Day High | 17.37 | Low High |
|||||
| Day Low | 16.54 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ALX Oncology Holdings Inc | ALXO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -0.06% | 16.86 | 15:58:36 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.81 | 16.54 | 17.37 | 16.86 | 16.87 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,160 | 466,719 | US$ 16.93 | US$ 7,903,393 | - | 3.9357 - 17.42 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:19:25 | 15 | US$ 16.86 | USD |
ALX Oncology Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 845.56M | 50.15M | - | 0 | -160.81M | -3.21 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ALX Oncology News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALXO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.60 | 17.37 | 13.88 | 15.82 | 429,580 | 1.26 | 8.08% |
| 1 Month | 11.25 | 17.37 | 10.49 | 13.95 | 625,493 | 5.61 | 49.87% |
| 3 Months | 14.75 | 17.42 | 10.49 | 13.91 | 491,521 | 2.11 | 14.31% |
| 6 Months | 6.77 | 17.42 | 6.485 | 12.85 | 463,269 | 10.09 | 149.04% |
| 1 Year | 5.54 | 17.42 | 3.9357 | 9.50 | 594,207 | 11.32 | 204.33% |
| 3 Years | 64.16 | 81.19 | 3.9357 | 17.35 | 406,485 | -47.30 | -73.72% |
| 5 Years | 30.44 | 117.45 | 3.9357 | 22.58 | 362,808 | -13.58 | -44.61% |
ALX Oncology Description
| ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. |
